Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have mutations in, or other dysregulation of, the mitogen-activated protein kinase; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia. The company was founded in 2014 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-500-8800
Debt
Current Ratio14.76
Quick Ratio14.76
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / Book6.11
Profitability
Net Income$-35,430,000.00
Net MarginsN/A
Return on Assets-39.47%
Miscellaneous
Employees32
OptionableOptionable
Kura Oncology (NASDAQ:KURA) Frequently Asked Questions
What is Kura Oncology's stock symbol?
Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."
How were Kura Oncology's earnings last quarter?
Kura Oncology Inc (NASDAQ:KURA) released its earnings results on Monday, November, 5th. The company reported ($0.40) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.41) by $0.01. View Kura Oncology's Earnings History.
When is Kura Oncology's next earnings date?
What price target have analysts set for KURA?
5 analysts have issued 1 year price targets for Kura Oncology's stock. Their forecasts range from $25.00 to $32.00. On average, they expect Kura Oncology's stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 79.9% from the stock's current price. View Analyst Price Targets for Kura Oncology.
What is the consensus analysts' recommendation for Kura Oncology?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kura Oncology.
What are Wall Street analysts saying about Kura Oncology stock?
Here are some recent quotes from research analysts about Kura Oncology stock:
- 1. According to Zacks Investment Research, "Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. " (1/8/2019)
- 2. HC Wainwright analysts commented, "Valuation and impediments to achieving price target. We reiterate our Buy rating and $31 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (12/3/2018)
Has Kura Oncology been receiving favorable news coverage?
Media coverage about KURA stock has trended positive on Thursday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Kura Oncology earned a news impact score of 2.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the next several days.
Who are some of Kura Oncology's key competitors?
Some companies that are related to Kura Oncology include Ultragenyx Pharmaceutical (RARE), Global Blood Therapeutics (GBT), Arena Pharmaceuticals (ARNA), Amicus Therapeutics (FOLD), Reata Pharmaceuticals (RETA), Endo International (ENDP), Mirati Therapeutics (MRTX), Opko Health (OPK), Heron Therapeutics (HRTX), Endocyte (ECYT), Xencor (XNCR), Innoviva (INVA), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD) and AnaptysBio (ANAB).
Who are Kura Oncology's key executives?
Kura Oncology's management team includes the folowing people:
- Dr. Troy Edward Wilson, Chairman, CEO & Pres (Age 49)
- Dr. Antonio Gualberto, Head of Devel. & Chief Medical Officer (Age 53)
- Dr. Marc Grasso, CFO & Chief Bus. Officer
- Mr. John Farnam, Chief Operating Officer
- Mr. Pete De Spain, VP of Investor Relations & Corp. Communications
How do I buy shares of Kura Oncology?
Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kura Oncology's stock price today?
One share of KURA stock can currently be purchased for approximately $16.12.
How big of a company is Kura Oncology?
Kura Oncology has a market capitalization of $626.09 million. The company earns $-35,430,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis. Kura Oncology employs 32 workers across the globe.
What is Kura Oncology's official website?
How can I contact Kura Oncology?
Kura Oncology's mailing address is 3033 SCIENCE PARK ROAD SUITE 220, SAN DIEGO CA, 92121. The company can be reached via phone at 858-500-8800 or via email at [email protected]
MarketBeat Community Rating for Kura Oncology (NASDAQ KURA)
MarketBeat's community ratings are surveys of what our community members think about Kura Oncology and other stocks. Vote "Outperform" if you believe KURA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KURA will underperform the S&P 500 over the long term. You may vote once every thirty days.
